BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim R, Lee JM, Shin CI, Lee ES, Yoon JH, Joo I, Kim SH, Hwang I, Han JK, Choi BI. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol. 2016;26:1808-1817. [PMID: 26373763 DOI: 10.1007/s00330-015-4005-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Ding Y, Rao S, Yang L, Chen C, Zeng M. Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis. Radiol Med. 2016;121:821-827. [PMID: 27449761 DOI: 10.1007/s11547-016-0669-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
2 An C, Rhee H, Han K, Choi JY, Park YN, Park MS, Kim MJ, Park S. Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. Eur Radiol. 2017;27:2610-2618. [PMID: 27770230 DOI: 10.1007/s00330-016-4634-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
3 Chen Y, Pan Y, Shen KR, Zhu XL, Lu CY, Li QH, Han SG, Fu YB, Xu XF, Yu RS. Contrast-enhanced multiple-phase imaging features of intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma with cirrhosis: A comparative study. Oncol Lett 2017;14:4213-9. [PMID: 28943929 DOI: 10.3892/ol.2017.6656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
4 Ni T, Shang XS, Wang WT, Hu XX, Zeng MS, Rao SX. Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size. Br J Radiol 2018;91:20180017. [PMID: 29791202 DOI: 10.1259/bjr.20180017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
5 Liang YY, Shao S, Kuang S, Chen J, Zhou J, He B, Zhang L, Zhang Y, Fowler KJ, Wang J. Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection. Can J Gastroenterol Hepatol 2021;2021:6639600. [PMID: 33748033 DOI: 10.1155/2021/6639600] [Reference Citation Analysis]
6 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
7 Zou X, Luo Y, Li Z, Hu Y, Li H, Tang H, Shen Y, Hu D, Kamel IR. Volumetric Apparent Diffusion Coefficient Histogram Analysis in Differentiating Intrahepatic Mass-Forming Cholangiocarcinoma from Hepatocellular Carcinoma. J Magn Reson Imaging. 2019;49:975-983. [PMID: 30277628 DOI: 10.1002/jmri.26253] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
8 Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y, Santillan C. LI-RADS® ancillary features on CT and MRI. Abdom Radiol (NY) 2018;43:82-100. [PMID: 28647768 DOI: 10.1007/s00261-017-1220-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
9 Kim YY, Park MS, Aljoqiman KS, Choi JY, Kim MJ. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Clin Mol Hepatol 2019;25:223-33. [PMID: 30661336 DOI: 10.3350/cmh.2018.0107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
10 Hwang J, Kim YK, Min JH, Choi S, Jeong WK, Hong SS, Kim H, Ahn S, Ahn HS. Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI. Eur Radiol 2017;27:4581-90. [DOI: 10.1007/s00330-017-4846-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Cannella R, Cunha GM, Catania R, Chupetlovska K, Borhani AA, Fowler KJ, Furlan A. Magnetic Resonance Imaging of Nonhepatocellular Malignancies in Chronic Liver Disease. Magn Reson Imaging Clin N Am 2021;29:404-18. [PMID: 34243926 DOI: 10.1016/j.mric.2021.05.009] [Reference Citation Analysis]
12 Lee SE, An C, Hwang SH, Choi JY, Han K, Kim MJ. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease. Eur Radiol. 2018;28:1551-1559. [PMID: 29134355 DOI: 10.1007/s00330-017-5119-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
13 Noreikaite J, Albasha D, Chidambaram V, Arora A, Katti A. Indeterminate liver lesions on gadoxetic acid-enhanced magnetic resonance imaging of the liver: Case-based radiologic-pathologic review. World J Hepatol 2021; 13(9): 1079-1097 [PMID: 34630876 DOI: 10.4254/wjh.v13.i9.1079] [Reference Citation Analysis]
14 Aslam A, Kamath A, Spieler B, Maschiocchi M, Sabottke CF, Chernyak V, Lewis SC. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 2021;46:3565-78. [PMID: 33856509 DOI: 10.1007/s00261-021-03076-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Woo H, Han JK, Kim JH, Hong ST, Uddin MH, Jang JJ. In-vivo monitoring of development of cholangiocarcinoma induced with C. sinensis and N-nitrosodimethylamine in Syrian golen hamsters using ultrasonography and magnetic resonance imaging: a preliminary study. Eur Radiol 2017;27:1740-7. [PMID: 27510623 DOI: 10.1007/s00330-016-4510-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Wang HQ, Yang C, Zeng MS, Rao SX, Ji Y, Weng X, Wang JY, Sheng RF. Magnetic resonance texture analysis for the identification of cytokeratin 19-positive hepatocellular carcinoma. Eur J Radiol 2019;117:164-70. [PMID: 31307643 DOI: 10.1016/j.ejrad.2019.06.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Mantripragada S, Chawla A. Cholangiocarcinoma - Part 2, Tumoral and Nontumoral Mimics and Imaging Features Helpful in Differentiation. Curr Probl Diagn Radiol 2021:S0363-0188(21)00033-5. [PMID: 33627221 DOI: 10.1067/j.cpradiol.2021.02.005] [Reference Citation Analysis]
18 Wengert GJ, Baltzer PA, Bickel H, Thurner P, Breitenseher J, Lazar M, Pones M, Peck-radosavljevic M, Hucke F, Ba-ssalamah A. Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging. Academic Radiology 2017;24:1491-500. [DOI: 10.1016/j.acra.2017.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
19 Ichikawa S, Isoda H, Shimizu T, Tamada D, Taura K, Togashi K, Onishi H, Motosugi U. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study. Eur Radiol 2020;30:5992-6002. [PMID: 32500195 DOI: 10.1007/s00330-020-06972-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Semelka RC, Nimojan N, Chandana S, Ramalho M, Palmer SL, DeMulder D, Parada Villavicencio C, Woosley J, Garon BL, Jha RC, Miller FH, Altun E. MRI features of primary rare malignancies of the liver: A report from four university centres. Eur Radiol 2018;28:1529-39. [PMID: 29079914 DOI: 10.1007/s00330-017-5102-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
21 Lee DH, Lee JM. Primary malignant tumours in the non-cirrhotic liver. Eur J Radiol. 2017;95:349-361. [PMID: 28987692 DOI: 10.1016/j.ejrad.2017.08.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
22 Krasnodębski M, Grąt M, Jastrzębski M, Szczęśniak M, Morawski M, Zając K, Patkowski W, Zieniewicz K. Unsatisfactory Long-term Results of Liver Transplant in Patients With Intrahepatic Cholangiocarcinoma. Transplant Proc 2020;52:2463-7. [PMID: 32327261 DOI: 10.1016/j.transproceed.2020.02.095] [Reference Citation Analysis]
23 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Reference Citation Analysis]
24 Seo N, Kim DY, Choi JY. Cross-Sectional Imaging of Intrahepatic Cholangiocarcinoma: Development, Growth, Spread, and Prognosis. AJR Am J Roentgenol. 2017;209:W64-W75. [PMID: 28570102 DOI: 10.2214/ajr.16.16923] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
25 Zamora-Valdes D, Heimbach JK. Liver Transplant for Cholangiocarcinoma. Gastroenterol Clin North Am. 2018;47:267-280. [PMID: 29735023 DOI: 10.1016/j.gtc.2018.01.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
26 Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 2020;30:370-82. [PMID: 31385048 DOI: 10.1007/s00330-019-06369-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
27 Panick CE, Ward RD, Coppa C, Liu PS. Hepatic capsular retraction: An updated MR imaging review. European Journal of Radiology 2019;113:15-23. [DOI: 10.1016/j.ejrad.2019.01.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Joo I, Lee JM, Yoon JH. Imaging Diagnosis of Intrahepatic and Perihilar Cholangiocarcinoma: Recent Advances and Challenges. Radiology 2018;288:7-13. [DOI: 10.1148/radiol.2018171187] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
29 Mamone G, Di Piazza A, Carollo V, Crinò F, Vella S, Cortis K, Miraglia R. Imaging of primary malignant tumors in non-cirrhotic liver. Diagnostic and Interventional Imaging 2020;101:519-35. [DOI: 10.1016/j.diii.2020.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
30 Ichikawa S, Motosugi U, Morisaka H, Kozaka K, Goshima S, Ichikawa T. Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study. Magn Reson Med Sci 2021;20:47-59. [PMID: 32101818 DOI: 10.2463/mrms.mp.2019-0193] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Kovač JD, Galun D, Đurić-Stefanović A, Lilić G, Vasin D, Lazić L, Mašulović D, Šaranović Đ. Intrahepatic mass-forming cholangiocarcinoma and solitary hypovascular liver metastases: is the differential diagnosis using diffusion-weighted MRI possible? Acta Radiol 2017;58:1417-26. [PMID: 28350257 DOI: 10.1177/0284185117695666] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Gutzeit A, Matoori S, Froehlich JM, von Weymarn C, Reischauer C, Kolokythas O, Goyen M, Hergan K, Meissnitzer M, Forstner R, Soyka JD, Doert A, Koh DM. Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command. Eur Radiol 2016;26:2714-22. [PMID: 26573682 DOI: 10.1007/s00330-015-4086-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
33 Beal EW, Cloyd JM, Pawlik TM. Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. J Clin Med 2020;10:E104. [PMID: 33396821 DOI: 10.3390/jcm10010104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Ganeshan D, Pickhardt PJ, Morani AC, Javadi S, Lubner MG, Elmohr MM, Duran C, Elsayes KM. Hepatic hemangioendothelioma: CT, MR, and FDG-PET-CT in 67 patients-a bi-institutional comprehensive cancer center review. Eur Radiol 2020;30:2435-42. [PMID: 32002639 DOI: 10.1007/s00330-019-06637-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Choi SH, Lee SS, Kim SY, Park SH, Park SH, Kim KM, Hong S, Yu E, Lee M. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid–enhanced MR Imaging and Dynamic CT. Radiology 2017;282:771-81. [DOI: 10.1148/radiol.2016160639] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
36 Park SH, Lee SS, Yu E, Kang HJ, Park Y, Kim SY, Lee SJ, Shin YM, Lee MG. Combined hepatocellular-cholangiocarcinoma: Gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 2017;46:267-80. [PMID: 27875000 DOI: 10.1002/jmri.25568] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
37 Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20:1019-41. [PMID: 31270973 DOI: 10.3348/kjr.2018.0636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
38 Hu XX, Wang WT, Yang L, Yang ZX, Liang HY, Ding Y, Ji Y, Zeng MS, Rao SX. MR features based on LI-RADS identify cytokeratin 19 status of hepatocellular carcinomas. Eur J Radiol 2019;113:7-14. [PMID: 30927962 DOI: 10.1016/j.ejrad.2019.01.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Wang M, Gao Y, Feng H, Warner E, An M, Jia J, Chen S, Fang M, Ji J, Gu X, Gao C. A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Cancer Med 2018;7:646-54. [PMID: 29473340 DOI: 10.1002/cam4.1341] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
40 Liang W, Wan D, Lu Q, Lin S, Chen Z. Dynamic enhancement patterns of small-diameter mass-forming intrahepatic cholangiocarcinomas on contrast-enhanced magnetic resonance imaging: Challenges faced by the radiologist. Medicine (Baltimore) 2017;96:e8351. [PMID: 29069015 DOI: 10.1097/MD.0000000000008351] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 You M, Yun S. Differentiating between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced MRI features: a systematic review and meta-analysis. Clinical Radiology 2019;74:406.e9-406.e18. [DOI: 10.1016/j.crad.2018.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Cha DI, Jang KM, Kim SH, Kang TW, Song KD. Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging. Eur Radiol 2017;27:4394-405. [DOI: 10.1007/s00330-017-4804-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
43 Li HL, Liu HP, Guo GWJ, Chen ZH, Zhou FQ, Liu P, Liu JB, Wan R, Mao ZQ. Imaging findings of inflammatory pseudotumor-like follicular dendritic cell tumors of the liver: Two case reports and literature review. World J Gastroenterol 2019; 25(45): 6693-6703 [PMID: 31832007 DOI: 10.3748/wjg.v25.i45.6693] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ronot M, Dioguardi Burgio M, Purcell Y, Pommier R, Brancatelli G, Vilgrain V. Focal lesions in cirrhosis: Not always HCC. Eur J Radiol 2017;93:157-68. [PMID: 28668410 DOI: 10.1016/j.ejrad.2017.05.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
45 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]
46 Han SB, Kim YK, Min JH, Ha SY, Jeong WK, Lee WJ. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Acta Radiol 2018;59:393-401. [PMID: 28760004 DOI: 10.1177/0284185117723040] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:149-57. [PMID: 28580538 DOI: 10.1007/s00261-017-1196-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]